HCV kinetics, quasispecies, and clearance in treated HCV-infected and HCV/HIV-1-coinfected patients with hemophilia

Hepatology

Volumn 44, Issue 5, 2006, Pages 1146-1157

  Shire, Norah J ^a   Horn, Paul S ^a   Rouster, Susan D ^a   Stanford, Sandra ^a   Eyster, M Elaine ^b   Sherman, Kenneth E ^a   Barsky, Rita ^c   Goedert, James ^d   Goodman, Zach ^e   Koziel, Margaret J ^f   Leissinger, Cindy ^g   Long, Gail ^h   Sanders, Jeffrey ^h   Steinberg, James ⁱ  

^a UNIVERSITY OF CINCINNATI   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c National Hemophilia Foundation   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g TULANE UNIVERSITY   (United States)

^h PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

ⁱ EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ARTICLE; BLOOD CLOTTING DISORDER; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEMOPHILIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; KINETICS; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SUPERINFECTION; TREATMENT RESPONSE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; FOLLOW-UP STUDIES; HEMOPHILIA A; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; REMISSION INDUCTION; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 33751018285     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21374     Document Type: Article

References (30)

1. Aach RD, Szmuness W, Mosley JW, Hollinger FB, Kahn RA, Stevens CE, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study. N Engl J Med 1981;304:989-994.
2. Troisi CL, Hollinger FB, Hoots WK, Contant C, Gill J, Ragni M, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993;81:412-418.
3. Goedert JJ, Brown DL, Hoots K, Sherman KE. Human immunodeficiency and hepatitis virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia 2004;10 (Suppl 4):205-210.
4. Soucie JM, Nuss R, Evatt B, Abdelhak A, Cowan L, Hill H, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-442.
5. Goedert JJ, Eyster ME, Lederman MM, Mandalaki T, De Moerloose P, White GC 2nd, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002;100:1584-1589.
6. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
7. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993;6:602-610.
8. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001;183:1112-1115.
9. Lichterfeld M, Schmeisser N, Qurishi N, Vogel M, Brackmann HH, Spengler U, et al. Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients. J Infect 2005;50:221-228.
10. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
11. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
12. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
14. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004;292:2839-2848.
15. Fried MW, Peter J, Hoots K, Gaglio PJ, Talbut D, Davis PC, et al. Hepatitis C in adults and adolescents with hemophilia: a randomized, controlled trial of interferon alfa-2b and ribavirin. HEPATOLOGY 2002;36:967-972.
16. Hayashi K, Fukuda Y, Nakano I, Katano Y, Yokozaki S, Toyoda H, et al. Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs. Haemophilia 2000;6:677-681.
17. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998;282:103-107.
18. Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003;188:1498-1507.
19. Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005;128:313-327.
20. Evaluation and Management of Drug-Induced Liver Injury Algorithm. In: Hepatitis Resource Network; 2005.
21. Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002;35:482-487.
22. Sherman KE, Rouster SD, Mendenhall C, Thee D. Hepatitis cRNA quasispecies complexity in patients with alcoholic liver disease. HEPATOLOGY 1999;30:265-270.
23. Eyster ME, Sherman KE, Goedert JJ, Katsoulidou A, Hatzakis A. Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia: The Multicenter Hemophilia Cohort Study. J Infect Dis 1999;179:1062-1069.
24. Daar ES, Lynn H, Donfield S, Gomperts E, Hilgartner MW, Hoots WK, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir. Immune Defic. Syndr 2001;26:466-472.
25. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-1732.
26. Qin H, Shire NJ, Keenan ED, Rouster SD, Eyster ME, Goedert JJ, et al. HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV. Blood 2005;105:533-541.
27. Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, et al. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection. J Virol 2005;79:3071-3083.
28. Abbate I, Lo Iacono O, Di Stefano R, Cappiello G, Girardi E, Longo R, et al. HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol 2004;40:831-836.
29. Neau D, Galperine T, Legrand E, Pitard V, Neau-Cransac M, Moreau JF, et al. T-lymphocyte populations in hepatitis C and HIV co-infected patients treated with interferon-alfa-2a and ribavirin. HIV Med 2003;4:120-126.
30. Shuhart MC, Sullivan DG, Bekele K, Harrington RD, Kitahata MM, Mathisen TL, et al. HIV infection and antiretroviral therapy effect on hepatitis C virus quasispecies variability. J Infect Dis 2006;193:1211-1218.